Journal of Sleep Research最新文献

{"title":"About the Other Side of Sleep Disorders: Improving Daytime Problems, Fatigue, Sleepiness, Cognitive Functioning and More.","authors":"Susanna Jernelöv, Kerstin Blom","doi":"10.1111/jsr.70164","DOIUrl":"https://doi.org/10.1111/jsr.70164","url":null,"abstract":"<p><p>Daytime impairments-such as fatigue, emotional instability, and cognitive difficulties-are increasingly acknowledged as core features of insomnia, yet they remain underrepresented in both research and treatment strategies. While CBT-I remains the gold standard for treating nocturnal symptoms, its effects on daytime functioning, which are often the primary concern for patients, are less robust, inconsistently measured, and poorly understood. This narrative review highlights the need to elevate daytime symptoms from secondary outcomes to central targets in both research and clinical practice. Key gaps include the lack of standardised and conceptually clear outcome measures, limited personalisation of CBT-I protocols, and insufficient understanding of the mechanisms linking improved sleep to daytime recovery. Moreover, the ethical implications of emerging digital assessment tools must be addressed to ensure that technological innovation does not come at the cost of participant trust or autonomy. To move the field forward, future research should prioritise daytime functioning as a primary endpoint, adopt ethically grounded multimodal assessment strategies, and explore adaptive, symptom-specific treatment designs. Finally, insomnia should be recognised not only as a disorder in its own right but also as a transdiagnostic and potentially preventable contributor to broader mental health problems. Addressing these challenges may lead to more effective, personalised, and patient-centred care for individuals living with insomnia.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70164"},"PeriodicalIF":3.9,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Associations of Physical Activity Volume, Intensity, and Timing With Sleep in Preschool-Aged Children.","authors":"Wendy Yajun Huang, Jie Feng, Cindy Hui-Ping Sit, John J Reilly, Asaduzzaman Khan","doi":"10.1111/jsr.70162","DOIUrl":"https://doi.org/10.1111/jsr.70162","url":null,"abstract":"<p><p>This study aimed to investigate the temporal relationships between accelerometer-derived physical activity metrics-specifically volume, intensity, and timing-with the preceding and subsequent nights' sleep in preschool-aged children. This analysis used the baseline data from a randomised controlled trial among 93 children (53 boys) aged 3-5.9 years who provided daily, repeated measures for at least four days. Open-source R package GGIR was used to generate daily measures of average acceleration, intensity gradient, timing of the most active 10 h (M10 start), sleep duration, sleep efficiency, and sleep midpoint. Linear mixed models were performed to examine temporal associations between waketime physical activity and the subsequent night's sleep, and between nocturnal sleep and physical activity the following day, at both within- and between-person levels. A higher intensity gradient compared to the personal average during the day predicted a lower sleep efficiency on the subsequent night (β = -10.71, 95% CI: -17.20, -4.21). At the between-person level, children with longer sleep duration (β = 0.87, 95% CI: 0.45, 1.29), a later sleep midpoint (β = 1.03, 95% CI: 0.79, 1.27), or lower sleep efficiency (-0.09, 95% CI: -0.14, -0.03) were more likely to have their active periods later in the following day. These findings suggest that the timing of physical activity and sleep midpoint showed consistent bidirectional associations at both within- and between-person levels. The findings suggest that incorporating lower intensity activities that are scheduled at appropriate times into daily routines may be crucial for better sleep for young children.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70162"},"PeriodicalIF":3.9,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep in Functional Motor Disorders: A Case-Control Polysomnographic Study.","authors":"Jiří Nepožitek, Simona Dostálová, Martin Jirásek, Gabriela Chaloupková, Zuzana Forejtová, Lucia Nováková, Veronika Rottová, Veronika Konvičná, Karel Šonka, Mark J Edwards, Tereza Serranová","doi":"10.1111/jsr.70163","DOIUrl":"https://doi.org/10.1111/jsr.70163","url":null,"abstract":"<p><p>Sleep problems are frequent in functional motor disorders (FMDs). Surprisingly, objective correlates of impaired sleep and its relationship to other comorbidities have been understudied, and no polysomnographic study is available. We aimed to map the polysomnographic parameters in the context of self-reported sleep and mood symptoms and search for comorbid sleep disorders in FMD and healthy controls. Thirty-seven patients (mean age [SD], 48.2 [10.6] years) with clinically definite FMD and 37 controls (48.6 [11.2] years) underwent structured medical and sleep history assessment, neurological examination and polysomnography and completed questionnaires for sleep quality, sleepiness, depression and anxiety. In FMD, specific sleep disorders were identified in our cohort, with 32% having restless legs syndrome, 38% clinically significant obstructive sleep apnoea and 8% periodic limb movements in sleep. FMD patients reported worse sleep quality (p < 0.001), higher sleepiness (p < 0.001), depression (p < 0.001) and anxiety (p < 0.001), had longer REM sleep latency (p < 0.001), worse sleep efficiency (p = 0.012) and increased wake ratio (p = 0.013). Furthermore, longer sleep latency (p = 0.030) and decreased REM sleep ratio (p = 0.027) in FMD reached nominal significance before adjustment for multiple comparisons. In FMD, subjective sleep quality positively correlated with depression (ρ = 0.54; p < 0.002) and anxiety (ρ = 0.61; p < 0.001) and subjective sleepiness correlated with depression (ρ = 0.42; p = 0.010). Self-reported measures did not correlate with any polysomnographic parameters. Polysomnography detected sleep structure changes in FMD. Sleep abnormalities, including impairments in REM sleep, should be considered in the management of FMD. Future studies should further explore the role of REM sleep disturbances in the pathophysiology of FMD.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70163"},"PeriodicalIF":3.9,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EEG Brain Rhythms During Resting-State Wakefulness and Sleep in Elderly Expert Meditators.","authors":"Pierre Champetier, Anaïs Hamel, Claire André, Valentin Ourry, Tristan Lacroix, Stéphane Rehel, Léa Chauveau, Sacha Haudry, Françoise Bertran, Vincent de la Sayette, Denis Vivien, Gaël Chételat, Antoine Lutz, Géraldine Rauchs","doi":"10.1111/jsr.70161","DOIUrl":"https://doi.org/10.1111/jsr.70161","url":null,"abstract":"<p><p>Meditation practice has been shown to impact resting-state EEG activity in expert meditators, but its benefits on sleep, which is particularly affected with age, are poorly understood. Our aim was to better understand the effects of long-term meditation practice on resting-state EEG and sleep in older adults. Twenty-seven elderly expert meditators (mean age ± SD: 70.7 ± 5.0 years) were compared to meditation-naive controls (69.3 ± 3.8 years) for sleep questionnaires (n = 135), polysomnography (n = 47) and resting-state EEG (n = 73). Sleep microstructure (slow waves and spindles) and EEG features (power, Kolmogorov complexity and permutation entropy (PE)) during resting-state, NREM, and REM sleep were compared between groups. Correlations were tested between the metrics that differed between the two groups and the level of meditation expertise within the meditator group. At rest, expert meditators exhibited lower delta power and higher delta PE than controls. Self-reported sleep quality did not differ between groups, but expert meditators slept longer, had reduced %N1, and higher %N2. During NREM sleep, they exhibited reduced delta power, increased alpha power, and greater theta PE. During REM sleep, they tended to show greater theta power. Finally, the composite score of meditation expertise was negatively associated with %N1, and tended to be positively associated with %N2 and REM sleep theta power. Overall, these results suggest that expert meditators showed more preserved brain activity at rest and sleep architecture, and exhibited EEG features suggesting higher cognitive states during NREM sleep. Clinical Trial Information: Name: Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training (Age-Well). Registration: EudraCT: 2016-002441-36; IDRCB: 2016-A01767-44; ClinicalTrials.gov Identifier: NCT02977819. (https://clinicaltrials.gov/ct2/show/NCT02977819?term=Age-Well&draw=2&rank=1).</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70161"},"PeriodicalIF":3.9,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Liraglutide on Intermittent Hypoxia-Induced Metabolic Dysfunction: From Bench to Bedside.","authors":"Cliona O'Donnell, Ailbhe King, Guillaume Vial, Emily O'Neill, Shane Crilly, Jonathan D Dodd, David J Murphy, Elise Belaidi, Jean-Louis Pepin, Claire Arnaud, Donal O'Shea, Silke Ryan","doi":"10.1111/jsr.70152","DOIUrl":"https://doi.org/10.1111/jsr.70152","url":null,"abstract":"<p><p>Intermittent hypoxia (IH)-mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking. Here, we hypothesised that a glucagon-like peptide (GLP)-1 (Liraglutide)-based weight loss regimen improves IH-induced metabolic perturbations. To test the hypothesis, we employed a comprehensive translational approach consisting of an innovative IH system for cell cultures, a murine IH model of diet-induced obese mice and a proof-of-concept randomised-controlled study in OSA (NCT04186494). Liraglutide significantly attenuated IH-mediated pro-inflammatory polarisation of bone marrow-derived murine macrophages in cell culture. However, this did not translate into improved IH-induced insulin resistance in C57Bl/6 mice fed on a high-fat diet despite significant weight loss. In OSA subjects without diabetes (n = 30, 50 ± 7 years, 80% males, apnoea-hypopnoea index [AHI] 50 ± 19/h, body mass index [BMI] 35.0 ± 3 kg/m²), Liraglutide in contrast to CPAP over 24 weeks led to improvement in insulin sensitivity (mean difference 1.91 ± 1.46 vs. -1.02 ± 2.75, p = 0.03) in correlation with reduction in anthropometric measures and visceral adipose tissue volume. However, in conjunction with its limited effect on OSA parameters, the combination of Liraglutide with CPAP therapy appeared superior to Liraglutide alone for improvement of other glycaemic parameters such as fasting glucose, glucose tolerance, or HbA1c. In summary, while Liraglutide is effective in mediating weight loss, a lack of improvement in IH-triggered metabolic dysfunction does not support its role as monotherapy for metabolic diseases in OSA.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70152"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corticotropin-Releasing Hormone (CRH) in Murine Narcolepsy: What Do Genetic and Immune Models Tell Us?","authors":"J Zhou, S Melzi, A L Morel, B Georges, T E Scammell, G J Lammers, R Fronczek, C Peyron","doi":"10.1111/jsr.70151","DOIUrl":"https://doi.org/10.1111/jsr.70151","url":null,"abstract":"<p><p>Narcolepsy type 1 is a chronic sleep disorder of putative autoimmune aetiology, primarily caused by the loss of orexin-producing neurons in the hypothalamus. An additional 88% reduction in corticotropin-releasing hormone-immunoreactive neurons of the paraventricular nucleus has been recently observed in post-mortem brains of individuals with narcolepsy type 1. It is, however, unknown whether this reduction is specific to the paraventricular nucleus or involves other brain regions expressing corticotropin-releasing hormone, such as the amygdala, which plays a central role in mood regulation, stress response and cataplexy. This study examined whether orexin neuron loss and/or hypothalamic neuroinflammation would affect the expression of corticotropin-releasing hormone and other neuropeptides, including melanin-concentrating hormone and histidine decarboxylase as a proof of concept. We used quantitative polymerase chain reaction to measure messenger RNA levels in three mice models of narcolepsy type 1: mice lacking orexin due to genetic disruption, mice with toxin-induced orexin neuron ablation and mice with autoimmune-mediated orexin neuron loss accompanied by hypothalamic neuroinflammation. We found no change in corticotropin-releasing hormone expression in both the hypothalamus and amygdala across all models, regardless of the timeline or mechanism of orexin loss. Similarly, the expression of melanin-concentrating hormone and histidine decarboxylase was unaffected. These findings suggest that the absence of orexin signalling alone is not sufficient to alter corticotropin-releasing hormone expression. Alternative mechanisms may account for the observation made in human narcolepsy type 1 post-mortem samples. Future human studies are warranted to identify the underlying processes and determine whether similar changes occur in other brain regions.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70151"},"PeriodicalIF":3.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint Trajectories of Insomnia Severity and Quality of Life Among Adults in Opioid Use Disorder Treatment: A Longitudinal Study With Parallel Process Latent Growth Curve Modelling.","authors":"Ariel Hoadley, Anju Felix, Salome Hailu, Jennifer D Ellis, Justin C Strickland, Jill A Rabinowitz, David Wolinsky, Martin Hochheimer, J Gregory Hobelmann, Andrew S Huhn","doi":"10.1111/jsr.70160","DOIUrl":"https://doi.org/10.1111/jsr.70160","url":null,"abstract":"<p><p>Sleep health is related to quality of life (QOL) in the general population, yet less is known about the trajectories of sleep and QOL during opioid use disorder (OUD) treatment. This study examined the joint trajectories of insomnia severity and QOL during the first 4 weeks of OUD treatment and tested predictors of the growth trajectories. Adults (N = 1607) in supervised withdrawal or residential OUD treatment completed surveys weekly for 4 weeks. Kruskal-Wallis tests and correlations examined differences in insomnia and QOL at intake by sociodemographic and clinical characteristics. An unconditional parallel process growth model examined the joint trajectories of sleep and QOL, and time-invariant covariates were added to a conditional growth model. In the unconditional growth model, insomnia and QOL were inversely related at intake (p < 0.001). Greater insomnia at intake was associated with more pronounced increases in QOL (p = 0.020), but QOL at intake did not predict changes in insomnia. Increases in insomnia severity were associated with worsening of QOL (p < 0.001). Patients who were younger (p = 0.020) and unemployed (p = 0.048) had greater improvements in insomnia, and patients who were younger (p = 0.001) and started treatment in a supervised withdrawal setting (p = 0.002) had greater improvements in QOL. Sleep quality and QOL are modifiable, so understanding their joint trajectories during OUD treatment can help improve quality of care and recovery. Targeting sleep disturbances early in treatment may support overall well-being and improve recovery outcomes.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70160"},"PeriodicalIF":3.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective Effect of a High Heat Conductivity Mattress Topper on Sleep During Heat Night.","authors":"Florane Pasquier, Jonathan Monin, Pierre-Emmanuel Tardo-Dino, Pascal Van Beers, Michael Quiquempoix, Mathias Guillard, Claire Deshayes, Vincent Beauchamps, Keyne Charlot, Laurent Bosquet, Mounir Chennaoui, Mathieu Nedelec, Fabien Sauvet","doi":"10.1111/jsr.70137","DOIUrl":"https://doi.org/10.1111/jsr.70137","url":null,"abstract":"<p><p>Environmental high temperatures can strongly affect sleep. Our aim was to assess the protective effect of a High Heat Conductivity Mattress topper (HHCM) on sleep duration and quality during one night's exposure to heat. HHCM efficacy was studied in a randomised double-blind crossover design in fifteen healthy young active subjects by overnight polysomnography in a temperature-controlled sleep laboratory, during 4 nights: 2 nights at 22°C (HHCM and Control Mattress, CM) and 2 nights at 32°C (HHCM and CM). Core body temperature (CBT), skin, room and mattress toppers surface temperatures were continuously recorded. We observed interactions between temperature and mattress conditions. At 22°C, we did not show any beneficial effect of HHCM compared to CM on sleep duration, but a longer N3 sleep stage duration (p = 0.03) and higher slow oscillation spectral density (p = 0.03). Heat night exposure (32°C) induced a decrease in total sleep time (TST) (-24.8 ± 7.1 min, p = 0.02), rapid eye movement (REM) duration (p = 0.03), sleep efficiency (p = 0.04), delta power spectral density (p = 0.03) and an increase of wake after sleep onset (p = 0.03) and transition between stages rate (p = 0.02). At 32°C, in comparison to CM, HHCM induced higher TST (+21.4 ± 16.1 min, p = 0.04), sleep efficiency (p = 0.04), REM duration (p = 0.03), and lower awakening duration (p = 0.03). These effects were associated with lower skin temperature and CBT. In conclusion, HHCM improves sleep quality and has a protective effect on CBT and sleep patterns during heat exposure in active healthy subjects. It could be a countermeasure for promoting sleep in particular during heat waves.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70137"},"PeriodicalIF":3.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yawning as Therapy? The Potential of the Conditioned Yawn Reflex as a Novel Treatment for Insomnia Disorder.","authors":"Colin A Espie","doi":"10.1111/jsr.70142","DOIUrl":"https://doi.org/10.1111/jsr.70142","url":null,"abstract":"<p><p>In 1986, Provine, the pioneer of yawning research wrote that 'Yawning may have the dubious distinction of being the least understood, common human behaviour' (p. 120); and so yawning remains some 40 years later, as something of a biological and social curiosity. However, this article examines contemporary scientific understanding of this age-old conundrum, proposing not only that yawning is a universal component of sleep's normal stimulus control paradigm, but that the conditioned yawn reflex might be harnessed to treat insomnia disorder. The core features of yawning as a ubiquitous, involuntary, periodic and conditionable behaviour; its associated actions on arousal, biofeedback and selective attention, as well as thermoregulation and airway patency; and its potential to signal and promote sleep engagement, lead to the proposition that the conditioned yawn reflex as therapy (CYRaT) is a feasible and potentially effective novel therapeutic for sleep-onset and sleep-maintenance insomnia disorder. Much research is required to test this hypothesis, but the article describes preliminary protocols for the administration and testing of CYRaT that might be utilised for this purpose.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70142"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDC25A Alleviates Obstructive Sleep Apnea-Hypopnea Syndrome With Hypertension and Inhibits Ferroptosis.","authors":"Xin Yang, Chunsheng Wang, Deng Ouyang, Haofeng Xu, Zhile Wu, HuiLing Ye, Ping Yan","doi":"10.1111/jsr.70155","DOIUrl":"https://doi.org/10.1111/jsr.70155","url":null,"abstract":"<p><p>Obstructive sleep apnea-hypopnea syndrome (OSAHS) is significantly correlated with hypertension. This investigation aimed to explore the effect of ferroptosis on OSAHS-hypertension. Ferroptosis-associated genes were screened based on the GSE205050 dataset and FerrDb database. An OSAHS-hypertension model was established by exposing Sprague Dawley rats to chronic intermittent hypoxia for 8 weeks, and human umbilical vein endothelial cells (HUVECs) were exposed to intermittent hypoxia in vitro. CDC25A was overexpressed using recombinant adeno-associated virus in vivo and plasmid transfection in vitro. Ferroptosis markers, oxidative stress indicators, blood pressure, abdominal aortic tissue histopathology, and endothelial cell viability/apoptosis were then assessed. Six ferroptosis-associated hub genes were identified, including CDC25A, EZH2, PARP1, HELLS, FANCD2, and RRM2, all of which were lowly expressed. In the rat model of OSAHS-hypertension, overexpression of CDC25A significantly reduced systolic and diastolic blood pressure as well as vascular wall thickness, while increasing α-SMA expression. Biochemical analyses showed that CDC25A decreased malondialdehyde (MDA) and Fe²⁺ levels while increasing glutathione (GSH), superoxide dismutase (SOD), and ferroptosis-associated proteins (FTH1, SLC7A11, GPX4). CDC25A overexpression in HUVECs ameliorated hypoxia-induced endothelial dysfunction by inhibiting ferroptosis and apoptosis and promoting cell survival; however, these protective effects were significantly abrogated by co-treatment with erastin. CDC25A inhibits OSAHS-hypertension progression and modulates ferroptosis-related pathways. This study identifies ferroptosis as a potential therapeutic target in OSAHS-associated hypertension, with CDC25A acting as a key regulatory factor.</p>","PeriodicalId":17057,"journal":{"name":"Journal of Sleep Research","volume":" ","pages":"e70155"},"PeriodicalIF":3.4,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}